Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note issued on Saturday. The firm set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Performance

NASDAQ:BCLI opened at $1.73 on Friday. Brainstorm Cell Therapeutics has a 52-week low of $1.05 and a 52-week high of $11.89. The stock has a fifty day moving average of $2.02 and a 200 day moving average of $2.56. The firm has a market capitalization of $9.86 million, a price-to-earnings ratio of -0.36 and a beta of 0.26.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.